NeuroBionics

NeuroBionics

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $40M

Overview

NeuroBionics is a private, pre-revenue biotech firm founded in 2017 and based in Austin, Texas. The company has developed a proprietary platform of microscale, multifunctional bioelectronic fibers designed for seamless integration with neural tissue. Its lead clinical program, evStim, aims to revolutionize deep brain stimulation (DBS) by enabling endovascular delivery, while its IO fiber serves as a research tool for neuroscience. Backed by foundational MIT research and industry leaders, NeuroBionics is positioned at the intersection of medical devices and regenerative medicine.

Neurological Disorders

Technology Platform

Microscale, flexible, bioelectronic fibers capable of multifunctional (electrical, optical, chemical, mechanical) neural interfacing for minimally invasive integration with the body.

Funding History

2
Total raised:$40M
Series A$32M
Seed$8M

Opportunities

The primary opportunity is to disrupt the large and growing Deep Brain Stimulation market by offering a minimally invasive, endovascular alternative that could expand patient access exponentially.
The flexible platform technology also allows for expansion into other neuromodulation and bioelectronic medicine indications.

Risk Factors

Key risks include the unproven clinical efficacy of endovascular stimulation, significant regulatory hurdles for a novel Class III medical device, and competition from both established medtech giants and other neurotech startups developing less invasive therapies.

Competitive Landscape

NeuroBionics competes with traditional DBS device makers (Medtronic, Abbott, Boston Scientific) and a growing field of neurotech startups exploring less invasive interfaces (e.g., Synchron, Paradromics). Its differentiation lies in its unique fiber-based, multifunctional, and endovascular approach.